Point-of-Care/Rapid Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User - Global Forecast to 2022

Table of Contents

1 INTRODUCTION 18

1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 18
1.4 MARKETS COVERED 19
1.4.1 YEARS CONSIDERED FOR THE STUDY 20
1.5 CURRENCY 20
1.6 LIMITATIONS 20
1.7 STAKEHOLDERS 20

2 RESEARCH METHODOLOGY 21

2.1 RESEARCH DATA 21
2.1.1 SECONDARY DATA 22
2.1.1.1 Secondary sources 23
2.1.2 PRIMARY DATA 23
2.1.2.1 Primary sources 25
2.1.2.2 Key Industry Insights 26
2.1.3 MARKET SIZE ESTIMATION METHODOLOGY 26
2.1.3.1 BOTTOM-UP APPROACH 27
2.1.3.2 TOP-DOWN APPROACH 27
2.1.4 RESEARCH DESIGN 28
2.1.5 MARKET DATA VALIDATION AND TRIANGULATION 29
2.1.6 ASSUMPTIONS FOR THE STUDY 30

3 EXECUTIVE SUMMARY 31

3.1 INTRODUCTION 31

4 PREMIUM INSIGHTS 35

4.1 POC DIAGNOSTICS: MARKET OVERVIEW 35
4.2 POC DIAGNOSTICS MARKET, BY PLATFORM 36
4.3 GEOGRAPHIC ANALYSIS: POC DIAGNOSTICS MARKET, BY END USER AND REGION 37
4.4 POC DIAGNOSTICS MARKET, BY PRODUCT 38
4.5 POC DIAGNOSTICS MARKET, BY PRESCRIPTION MODE 38
4.6 GEOGRAPHIC SNAPSHOT OF THE POC DIAGNOSTICS MARKET 39
 

5 MARKET OVERVIEW 40

5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 DRIVERS 42
5.2.1.1 High prevalence of infectious diseases in developing countries 42
5.2.1.2 Increasing incidence of target diseases 42
5.2.1.3 Rising usage of home-based POC devices 44
5.2.1.4 Growing government support 44
5.2.1.5 Technological advancements and new product launches 45
5.2.1.6 Growing number of regulatory approvals for novel immunoassay techniques 45
5.2.1.7 Shortage of skilled laboratory technicians 45
5.2.1.8 Rising number of CLIA-waived POC tests 46
5.2.2 RESTRAINTS 47
5.2.2.1 Product recalls: Hampering user confidence 47
5.2.2.2 Pricing pressure owing to reimbursement cuts and budget constraints 47
5.2.2.3 Stringent and time-consuming regulatory policies are significantly increasing gestation period for product launches 48
5.2.3 OPPORTUNITIES 48
5.2.3.1 Growth opportunities in emerging markets 48
5.2.3.2 Healthcare decentralization —Converting lab tests to POC tests 49
5.2.3.3 Increasing number of conferences and events 50
5.2.3.4 POC tests with multiplexing capabilities 50
5.2.4 CHALLENGES 51
5.2.4.1 Lack of alignment with definitive central lab methods 51
5.2.4.1.1 Disadvantages of POC testing over central lab methods 51
5.2.4.2 Inadequate knowledge about the use of POC devices in professional settings 51
5.2.4.3 Reluctance towards changing existing diagnostic practices 52
5.2.4.4 High cost of devices 52
5.2.5 EMERGING APPLICATIONS OF POINT-OF-CARE TESTING 52
5.2.5.1 Sepsis biomarkers 52
5.2.5.2 Stroke markers 53
5.2.5.3 Thyroid testing 54
5.2.5.4 DNA testing 54
5.2.5.5 Endocrine testing 55
 

6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 56

6.1 INTRODUCTION 57
6.2 GLUCOSE MONITORING PRODUCTS 58
6.2.1 STRIPS 61
6.2.2 METERS 61
6.2.3 LANCETS & LANCING DEVICES 61
6.3 CARDIOMETABOLIC TESTING PRODUCTS 62
6.3.1 CARDIAC MARKER TESTING PRODUCTS 63
6.3.2 BLOOD GAS/ELECTROLYTES TESTING PRODUCTS 64
6.3.3 HBA1C TESTING PRODUCTS 66
6.4 INFECTIOUS DISEASE TESTING PRODUCTS 67
6.4.1 INFLUENZA TESTING PRODUCTS 69
6.4.2 HIV TESTING PRODUCTS 70
6.4.3 HEPATITIS C TESTING PRODUCTS 71
6.4.4 SEXUALLY TRANSMITTED DISEASE (STD) TESTING PRODUCTS 73
6.4.5 HEALTHCARE-ASSOCIATED INFECTION (HAI) TESTING PRODUCTS 74
6.4.6 RESPIRATORY INFECTION TESTING PRODUCTS 75
6.4.7 TROPICAL DISEASE TESTING PRODUCTS 76
6.4.8 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 77
6.5 COAGULATION TESTING PRODUCTS 78
6.5.1 PT/INR TESTING PRODUCTS 80
6.5.2 ACTIVATED CLOTTING TIME (ACT/APTT) TESTING PRODUCTS 81
6.6 PREGNANCY AND FERTILITY TESTING PRODUCTS 82
6.6.1 PREGNANCY TESTING PRODUCTS 83
6.6.2 FERTILITY TESTING PRODUCTS 84
6.7 TUMOR/CANCER MARKER TESTING PRODUCTS 85
6.8 URINALYSIS TESTING PRODUCTS 86
6.9 CHOLESTEROL TESTING PRODUCTS 87
6.10 HEMATOLOGY TESTING PRODUCTS 89
6.11 DRUGS-OF-ABUSE TESTING PRODUCTS 90
6.12 FECAL OCCULT TESTING PRODUCTS 91
6.13 OTHER POC PRODUCTS 92

7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM 94

7.1 INTRODUCTION 95
7.2 LATERAL FLOW ASSAYS (IMMUNOCHROMATOGRAPHY TESTS) 96
7.3 DIPSTICKS 97
7.4 MICROFLUIDICS 98
7.5 MOLECULAR DIAGNOSTICS 99
7.6 IMMUNOASSAYS 100
 

8 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE 102

8.1 INTRODUCTION 103
8.2 PRESCRIPTION-BASED TESTING 104
8.3 OTC TESTING 105

9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER 107

9.1 INTRODUCTION 108
9.2 PROFESSIONAL DIAGNOSTIC CENTERS 109
9.2.1 OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS 110
9.2.2 HOSPITALS/CRITICAL CARE CENTERS 111
9.3 HOME CARE 112
9.4 RESEARCH LABORATORIES 113
9.5 OTHER END USERS 114

10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 116

10.1 INTRODUCTION 117
10.2 NORTH AMERICA 118
10.2.1 US 122
10.2.2 CANADA 126
10.3 EUROPE 129
10.3.1 GERMANY 133
10.3.2 FRANCE 136
10.3.3 UK 139
10.3.4 REST OF EUROPE (ROE) 142
10.4 ASIA PACIFIC 144
10.4.1 JAPAN 148
10.4.2 CHINA 151
10.4.3 INDIA 154
10.4.4 REST OF ASIA PACIFIC 157
10.5 REST OF THE WORLD (ROW) 161
10.5.1 LATIN AMERICA 163
10.5.2 MIDDLE EAST & AFRICA 165

11 COMPETITIVE LANDSCAPE 169

11.1 OVERVIEW 169
11.2 MARKET SHARE ANALYSIS, 2016 170
11.3 COMPETITIVE SCENARIO AND TRENDS 171
11.3.1 PRODUCT LAUNCHES 171
11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 171
11.3.3 PRODUCT APPROVALS 172
11.3.4 ACQUISITIONS 172

12 COMPANY PROFILES 173

(Business Overview, Products Offered, Recent Developments, Mnm View)*
12.1 ABBOTT LABORATORIES 173
12.2 ACCUBIOTECH 176
12.3 BECTON, DICKINSON, AND COMPANY (BD) 179
12.4 CHEMBIO DIAGNOSTICS 182
12.5 DANAHER CORPORATION 185
12.6 EKF DIAGNOSTICS 188
12.7 INSTRUMENTATION LABORATORY (A WERFEN COMPANY) 191
12.8 JOHNSON & JOHNSON 193
12.9 NOVA BIOMEDICAL 196
12.10 PTS DIAGNOSTICS (A PART OF SINOCARE INC.) 199
12.11 QUIDEL 201
12.12 ROCHE DIAGNOSTICS (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.) 204
12.13 SEKISUI DIAGNOSTICS 208
12.14 SIEMENS 211
12.15 TRINITY BIOTECH 215
*Business Overview, Products Offered, Recent Developments, Mnm View might not be captured in case of unlisted companies.
13 APPENDIX 217

LIST OF TABLES

TABLE 1 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 58
TABLE 2 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2015–2022 (USD MILLION) 60
TABLE 3 GLUCOSE MONITORING METERS MARKET, BY REGION, 2015–2022 (UNITS) 60
TABLE 4 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 61
TABLE 5 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY TYPE, 2015–2022 (USD MILLION) 62
TABLE 6 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 62
TABLE 7 CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION,
2015–2022 (USD MILLION) 64
TABLE 8 CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (UNITS) 64
TABLE 9 BLOOD GAS/ELECTROLYTES TESTING PRODUCTS MARKET, BY REGION,
2015–2022 (USD MILLION) 65
TABLE 10 BLOOD GAS/ELECTROLYTES TESTING ANALYZERS MARKET, BY REGION,
2015–2022 (UNITS) 66
TABLE 11 HBA1C TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 67
TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2015–2022 (USD MILLION) 68
TABLE 13 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 68
TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS,
BY REGION, 2015–2022 (USD MILLION) 69
TABLE 15 INFLUENZA TESTING ANALYZERS MARKET, BY REGION, 2015–2022 (UNITS) 70
TABLE 16 HIV TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 71
TABLE 17 HIV TESTING ANALYZERS MARKET, BY REGION, 2015–2022 (UNITS) 71
TABLE 18 HEPATITIS C TESTING PRODUCTS MARKET, BY REGION,
2015–2022 (USD MILLION) 72
TABLE 19 HEPATITIS C TESTING ANALYZERS MARKET, BY REGION, 2015–2022 (UNITS) 73
TABLE 20 STD TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 74
TABLE 21 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 75
TABLE 22 RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY REGION,
2015–2022 (USD MILLION) 76
TABLE 23 TROPICAL DISEASE TESTING PRODUCTS MARKET, BY REGION,
2015–2022 (USD MILLION) 77
TABLE 24 OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION,
2015–2022 (USD MILLION) 78
TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION TESTING PRODUCTS, BY TYPE, 2015–2022 (USD MILLION) 79
TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 80
TABLE 27 COAGULATION TESTING ANALYZERS MARKET, BY REGION, 2015–2022 (UNITS) 80
TABLE 28 PT/INR TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 81
TABLE 29 ACT/APTT TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 82
TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2015–2022 (USD MILLION) 82
TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 83
TABLE 32 PREGNANCY TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 84
TABLE 33 FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 85
TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 86
TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 87
TABLE 36 URINALYSIS TESTING ANALYZERS MARKET, BY REGION, 2015–2022 (UNITS) 87
TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 88
TABLE 38 CHOLESTEROL TESTING ANALYZERS MARKET, BY REGION, 2015–2022 (UNITS) 88
TABLE 39 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 89
TABLE 40 HEMATOLOGY TESTING ANALYZERS MARKET, BY REGION, 2015–2022 (UNITS) 90
TABLE 41 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 91
TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 92
TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 93
TABLE 44 POC DIAGNOSTICS MARKET, BY PLATFORM, 2015–2022 (USD MILLION) 95
TABLE 45 LATERAL FLOW ASSAYS MARKET, BY REGION, 2015–2022 (USD MILLION) 96
TABLE 46 DIPSTICKS MARKET, BY REGION, 2015–2022 (USD MILLION) 97
TABLE 47 MICROFLUIDICS MARKET, BY REGION, 2015–2022 (USD MILLION) 98
TABLE 48 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 100
TABLE 49 IMMUNOASSAYS MARKET, BY REGION, 2015–2022 (USD MILLION) 101
TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 103
TABLE 51 PRESCRIPTION-BASED TESTING MARKET, BY REGION, 2015–2022 (USD MILLION) 105
TABLE 52 OTC TESTING PRODUCTS MARKET, BY REGION, 2015–2022 (USD MILLION) 106
TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 108
TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR PROFESSIONAL DIAGNOSTIC CENTERS, BY TYPE, 2015–2022 (USD MILLION) 109
TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR PROFESSIONAL DIAGNOSTIC CENTERS, BY REGION, 2015–2022 (USD MILLION) 109
TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS, BY REGION, 2015–2022 (USD MILLION) 111
TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS/CRITICAL CARE CENTERS, BY REGION, 2015–2022 (USD MILLION) 112
TABLE 58 POINT-OF-CARE MARKET FOR HOME CARE, BY REGION,
2015–2022 (USD MILLION) 113
TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES,
BY REGION, 2015–2022 (USD MILLION) 114
TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2015–2022 (USD MILLION) 115
TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 118
TABLE 62 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 120
TABLE 63 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 120
TABLE 64 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015–2022 (USD MILLION) 121
TABLE 65 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 121
TABLE 66 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 122
TABLE 67 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 124
TABLE 68 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 125
TABLE 69 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 125
TABLE 70 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 125
TABLE 71 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 127
TABLE 72 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 128
TABLE 73 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 128
TABLE 74 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 129
TABLE 75 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 131
TABLE 76 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 131
TABLE 77 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 132
TABLE 78 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 132
TABLE 79 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 133
TABLE 80 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 135
TABLE 81 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015–2022 (USD MILLION) 135
TABLE 82 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015-2022 (USD MILLION) 136
TABLE 83 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 136
TABLE 84 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 137
TABLE 85 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 138
TABLE 86 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 138
TABLE 87 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 139
TABLE 88 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 140
TABLE 89 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 141
TABLE 90 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 141
TABLE 91 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 141
TABLE 92 ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 143
TABLE 93 ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 143
TABLE 94 ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 144
TABLE 95 ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 144
TABLE 96 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 146
TABLE 97 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 146
TABLE 98 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 147
TABLE 99 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 147
TABLE 100 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 148
TABLE 101 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 149
TABLE 102 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 150
TABLE 103 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 150
TABLE 104 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 151
TABLE 105 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 152
TABLE 106 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 153
TABLE 107 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 153
TABLE 108 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 154
TABLE 109 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 156
TABLE 110 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015-2022 (USD MILLION) 156
TABLE 111 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 157
TABLE 112 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 157
TABLE 113 ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 159
TABLE 114 ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 159
TABLE 115 ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 160
TABLE 116 ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 160
TABLE 117 ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 161
TABLE 118 ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 161
TABLE 119 ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2015–2022 (USD MILLION) 162
TABLE 120 ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 162
TABLE 121 ROW: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 163
TABLE 122 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 164
TABLE 123 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2015–2022 (USD MILLION) 164
TABLE 124 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2015–2022 (USD MILLION) 165
TABLE 125 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 165
TABLE 126 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 167
TABLE 127 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PRESCRIPTION MODE, 2015–2022 (USD MILLION) 167
TABLE 128 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2015-2022 (USD MILLION) 168
TABLE 129 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 168

LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY STEPS 21
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 24
FIGURE 3 DATA TRIANGULATION 29
FIGURE 4 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017 VS. 2022 31
FIGURE 5 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE,
2017 VS. 2022 32
FIGURE 6 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2017 VS. 2022 33
FIGURE 7 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022 33
FIGURE 8 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2017 (USD MILLION) 34
FIGURE 9 HIGH PREVALENCE OF INFECTIOUS DISEASES IS DRIVING THE ADOPTION OF POC DEVICES ACROSS THE GLOBE 35
FIGURE 10 LATERAL FLOW ASSAYS SEGMENT WILL CONTINUE TO DOMINATE
THE MARKET IN 2022 36
FIGURE 11 PROFESSIONAL DIAGNOSTIC CENTERS SEGMENT TO DOMINATE THE GLOBAL POC DIAGNOSTICS END-USER MARKET IN 2017 37
FIGURE 12 GLUCOSE MONITORING SEGMENT TO DOMINATE THE POC DIAGNOSTICS PRODUCTS MARKET DURING THE FORECAST PERIOD 38
FIGURE 13 PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE THE POC DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 38
FIGURE 14 NORTH AMERICA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 39
FIGURE 15 POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41
FIGURE 16 ESTIMATED NUMBER OF DIABETIC PATIENTS, BY REGION, 2015 VS. 2040 43
FIGURE 17 THE INFECTIOUS DISEASE TESTING PRODUCTS SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 57
FIGURE 18 MOLECULAR DIAGNOSTICS SEGMENT TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 95
FIGURE 19 OTC TESTING SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD 103
FIGURE 20 HOME CARE TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD 108
FIGURE 21 POINT-OF-CARE DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION (2017–2022) 117
FIGURE 22 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 119
FIGURE 23 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 130
FIGURE 24 APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 145
FIGURE 25 KEY DEVELOPMENTS BY LEADING MARKET PLAYERS IN THE MARKET, 2015–2017 169
FIGURE 26 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS, 2016 170
FIGURE 27 ABBOTT LABORATORIES: COMPANY SNAPSHOT 173
FIGURE 28 BD: COMPANY SNAPSHOT 179
FIGURE 29 CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT 182
FIGURE 30 DANAHER CORPORATION: COMPANY SNAPSHOT 185
FIGURE 31 EKF DIAGNOSTICS: COMPANY SNAPSHOT 188
FIGURE 32 JOHNSON & JOHNSON: COMPANY SNAPSHOT 193
FIGURE 33 QUIDEL: COMPANY SNAPSHOT 201
FIGURE 34 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 204
FIGURE 35 SIEMENS: COMPANY SNAPSHOT 212
FIGURE 36 TRINITY BIOTECH: COMPANY SNAPSHOT 215

当レポートのプレスリリースは発行されておりません。